Lipedematous scalp: Case report with radiologic, histopathologic, and management insights Authors: Lakshmi L Vallabhaneni, Alyssa M Thompson, Kim Hiatt, Mahdieh Jedlowski Published: 2026 Introduction Lipedematous alopecia (LA) is a rare condition associated with thickening of the subcutaneous layer of the scalp with abnormal hair growth. Without associated alopecia, it is referred to as lipedematous scalp (LS). Literature on LA and LS remains limited with the pathogenesis still unknown, and treatments based on individual case reports. Herein we report a case of a 52-year-old woman with a new diagnosis of LA and review the literature on treatment. Case report A 52-year-old female with a past medical history of lupus erythematosus (not on systemic treatment), endocrine pancreatic insufficiency, and B2 deficiency presented to the dermatology clinic with a 7-year history of patchy alopecia and symptomatic palpable bogginess of the frontal, parietal and occipital scalp (Fig 1). Associated symptoms included tenderness and pruritus of the scalp. She denied any accompanying systemic symptoms. Life stressors were her only identifiable trigger. Trichoscopy revealed follicular miniaturization of right parietal, vertex and occipital scalp, with notable lack of perifollicular erythema/scaling, exclamation mark hairs, yellow dots, and inflammatory papules/nodules. On palpation of the scalp, there was significant bogginess. Clinical exam with scalp bogginess and patchy alopecia. Punch biopsy of the right parietal scalp showed mild focal perifollicular lymphohistiocytic infiltrate with subcutaneous layer encroachment into the reticular dermis and sebaceous lobules (Fig 2). Computed tomography head showed increased subcutaneous fat in an asymmetric lobular configuration, most pronounced at the bilateral parietal scalp, measuring a maximum of 19 mm on the right and 45 mm on the left (Fig 3). Parietal scalp biopsy demonstrating expansion of the subcutis by normally formed, mature adipocytes extending in clusters and as single cells into the overlying reticular dermis. The superficial reticular dermis exhibits increased edema with a moderate perifollicular lymphohistiocytic inflammatory infiltrate, accompanied by a decreased number of follicular units. CT scan highlighting increased subcutaneous fat layer of the scalp, as demonstrated by the arrows. CT, Computed tomography. A diagnosis of LA was made based on clinical history, physical exam, histology, and imaging. Due to the condition's disfigurement and impact on quality of life, the patient opted for treatment. Options discussed included intralesional steroids, mycophenolate mofetil (MMF), oral minoxidil, and fat-reducing therapies like Kybella. Ultimately, the patient received 2 rounds of intralesional triamcinolone acetonide injections, spaced 4 weeks apart. The first round (3 mL at 20 mg/mL) targeted the occipital and vertex scalp, while the second round (1.5 mL at 40 mg/mL) targeted the vertex scalp. Follow-up showed improvement in scalp bogginess, hair loss, tenderness, and pruritus (Fig 4). However, the injections resulted in debilitating headaches, so we pivoted therapies. The patient attempted oral minoxidil 2.5 mg/day for 3 months with minimal improvement. She ultimately opted to explore scalp reduction surgery and alternative options such as wigs. Before (left picture) versus after (right picture) ILK-20 and ILK-40 demonstrating hair growth. ILK, Intralesional triamcinolone acetonide. Discussion LS and LA are rare conditions marked by thickened subcutaneous adipose tissue of the scalp, with LA having associated hair loss. Around 115 cases have been reported, primarily affecting middle aged females (83%) with an increased prevalence in African Americans.1 Symptoms include pruritus, pain, and headache. The etiology remains unclear, though the female predominance suggests hormonal factors are involved. Leptin may play a role in regulating fat distribution and lipoptosis.2 Obesity, another contributing factor, may impair lymphatic flow, causing dermal edema, scalp thickening, pruritus, and tenderness.3 Familial cases and associations with autoimmune diseases like lupus erythematosus, Hashimoto's thyroiditis, Sjögren's syndrome, and alopecia areata have also been reported.1 Diagnosis of LS and LA relies on clinical examination and histopathological findings, with increased subcutaneous fat thickness being the key feature. Normal adult scalp thickness is 5-6 mm, though can increase to a mean of ∼11 mm in patient with a BMI >40, while measurements in LS and LA range from 9 to 31.2 mm.1,4 Our case shows a max thickness of 45 mm involving the left parietal scalp making it the thickest case reported in the literature to date. Other histopathologic features include epidermal changes (hyperkeratosis, acanthosis, follicular plugging), dermal changes (edema, lymphatic dilatation, elastic fiber fragmentation), and subcutaneous changes (disrupted fat architecture, free-floating lipid droplets). Imaging methods such as Magnetic Resonance Imaging, CT, and ultrasonography measure scalp thickness and support the diagnosis. Currently, there are no established guidelines for the treatment of LA and LS. However, treatment in case reports have focused on symptom management with attempts to decrease scalp thickness and increase hair density. There have been varying reports on the effects of topical, intralesional, and systemic steroids. Topical steroids have been trialed with improvement in hair regrowth at the 6 week mark in a patient with LA, though scalp thickness was not assessed.5 Interestingly, intralesional steroids showed worsening of LA in one patient.6 There are mixed reports on systemic steroids with one report of prednisone for 3 months showing an increase in hair growth and reduction in scalp thickness, though another report showed no benefit.7,8 Other systemic therapies have been trialed. A combination of potent topical steroids, doxycycline, and hydroxychloroquine 200 mg BID reduced scalp pain but had no impact on scalp thickness after 6 months.9 MMF has shown the most promising results. One patient treated with 1 g/d for 10 months showed significant improvement in hair density and reduction in scalp thickness at 3 months. By 10 and 16 months (6 months post-MMF), the patient had complete hair recovery and resolution of scalp inflammation.6 Combining MMF 1 g/d with topical minoxidil has shown additive benefit in hair growth and reduction in scalp pain, though may increase scalp thickness.9 Surgical options such as debulking have been trialed with success. A 67-year-old woman with LA, who failed topical minoxidil, underwent surgical debulking and scalp reduction, resulting in improved hair growth and decreased scalp thickness. At 12-month follow-up, there was continued remission.2 Despite its promising results, no other cases have explored this treatment method. Lastly, one case reported spontaneous resolution of LA. A 69-year-old woman, diagnosed in 2003, showed complete resolution 13 years later. computed tomography scans revealed reduced scalp thickness and subcutaneous fat from 19.2 mm in 2003 to 6 mm in 2016.10 The authors noted this as the first-ever case of spontaneous recovery, with no clear explanation. Conclusion In conclusion, LA and LS are rare scalp conditions with unknown pathogenesis and no consensus on treatment guidelines. Physical exam findings, biopsy, and imaging aid in diagnosis, and management focuses on symptomatic relief, improving hair growth, and decreasing scalp thickness. Immunomodulatory therapies, such as MMF, may be a promising option, though additional research is needed to better define its role. Further studies are required to clarify pathogenesis, diagnostic criteria, and treatment strategies. Conflicts of interest None disclosed. Footnotes Funding sources: None. Patient consent: The authors obtained written consent from the patient(s) for their photographs and medical information to be published in print and online, with the understanding that this information may be publicly available. IRB approval status: Not required. References